RP

Ruda Cui, PhD

Scientist II at Neurogene

Ruda Cui, PhD has a diverse work experience spanning over several years. They started their career in 2011 as an undergraduate researcher at Penn State University, where they focused on studying neuromuscular mechanisms in Drosophila using molecular and genetic methods. Following this, they worked as a Summer Undergraduate Research Intern at Hershey Medical Center in 2012, where they contributed to data analysis for a publication on muscle mechanoreflex activation. In 2014, Ruda joined Rice University as a PhD Graduate Student, specializing in a yet unspecified field. They completed their PhD in 2019 and then transitioned to Lonza as an R&D Research Associate. Their role at Lonza lasted till early 2020 when they moved on to Neurogene Inc. as a Research Scientist. Currently, they hold the position of Scientist II at Neurogene Inc., with their tenure starting in 2022.

Ruda Cui, PhD, has an extensive education history in the field of biology and biochemistry. Ruda completed their Doctor of Philosophy (PhD) in Biochemistry and Cell Biology at Rice University from 2014 to 2019. Prior to that, they pursued a Bachelor of Science (B.S.) in Biology at the Schreyer Honors College, Penn State University, from 2010 to 2014. Additionally, during the same period, they also earned a Bachelor of Science (B.S.) in Genetics from Penn State University. It is evident that Ruda Cui has a strong foundation in the natural sciences, which has shaped their expertise and career path in the field of biology and biochemistry.

Location

Houston, United States

Links


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Neurogene

Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.


Industries

Employees

11-50

Links